Quantum BioPharma Ltd. (QNTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has a cash flow conversion efficiency ratio of 1.155x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($-1.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see QNTM market cap overview for the company's overall valuation and market capitalisation.
Quantum BioPharma Ltd. - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Quantum BioPharma Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quantum BioPharma Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quantum BioPharma Ltd. ranked by their cash flow conversion efficiency. Explore Quantum BioPharma Ltd. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
West Coast Silver Ltd
AU:WCE
|
-1.634x |
|
CLPS INC. DL-0001
F:1UK
|
N/A |
|
Isofol Medical AB
ST:ISOFOL
|
-0.100x |
|
Nanogroup SA
WAR:NNG
|
-0.141x |
|
Bartronics India Limited
NSE:ASMS
|
-0.006x |
|
Next Hydrogen Solutions Inc.
V:NXH
|
-0.339x |
|
Inalways
TWO:5398
|
0.080x |
|
Duckshin Housing Co. Ltd
KQ:090410
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Quantum BioPharma Ltd. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Quantum BioPharma Ltd. from 2015 to 2025. View Quantum BioPharma Ltd. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.09 Million | $-8.38 Million | -1.646x | -149.83% |
| 2024-12-31 | $10.44 Million | $-6.88 Million | -0.659x | +21.47% |
| 2023-12-31 | $12.91 Million | $-10.83 Million | -0.839x | +9.59% |
| 2022-12-31 | $30.54 Million | $-28.33 Million | -0.928x | -142.05% |
| 2021-12-31 | $54.13 Million | $-20.75 Million | -0.383x | +27.26% |
| 2020-12-31 | $36.31 Million | $-19.13 Million | -0.527x | -39.39% |
| 2019-12-31 | $36.28 Million | $-13.71 Million | -0.378x | -4.33% |
| 2018-12-31 | $37.47 Million | $-13.58 Million | -0.362x | -2901.19% |
| 2017-12-31 | $9.87 Million | $-119.18K | -0.012x | -102.41% |
| 2016-12-31 | $-54.30K | $-27.24K | 0.502x | +46055.76% |
| 2015-12-31 | $-58.37K | $-63.44 | 0.001x | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more